Aclaris Therapeutics Announces FDA Fast Track Designation For Modzatinib In Moderate To Severe Lichen Planus; Phase 2b Trial Initiation Expected In Q4 2026

뉴스 본문을 불러오고 있어요.

Aclaris Therapeutics Announces FDA Fast Track Designation For Modzatinib In Moderate To Severe Lichen Planus; Phase 2b Trial Initiation Expected In Q4 2026 | 웨이프 WAPE

Aclaris Therapeutics Announces FDA Fast Track Designation For Modzatinib In Moderate To Severe Lichen Planus; Phase 2b Trial Initiation Expected In Q4 2026

기사 요약

관련 종목

댓글 —